These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 36601751)
41. Morphologic and biochemical studies of canine mucopolysaccharidosis I. Shull RM; Helman RG; Spellacy E; Constantopoulos G; Munger RJ; Neufeld EF Am J Pathol; 1984 Mar; 114(3):487-95. PubMed ID: 6320652 [TBL] [Abstract][Full Text] [Related]
42. Histopathologic changes of the ear in canine models of mucopolysaccharidosis types I and VII. Hordeaux J; Deniaud J; Bemelmans I; Bertrand L; Moreau S; Amiaud J; Wyers M; Cherel Y; Colle MA Vet Pathol; 2011 May; 48(3):616-26. PubMed ID: 20930106 [TBL] [Abstract][Full Text] [Related]
44. Pathogenesis of mitral valve disease in mucopolysaccharidosis VII dogs. Bigg PW; Baldo G; Sleeper MM; O'Donnell PA; Bai H; Rokkam VR; Liu Y; Wu S; Giugliani R; Casal ML; Haskins ME; Ponder KP Mol Genet Metab; 2013 Nov; 110(3):319-28. PubMed ID: 23856419 [TBL] [Abstract][Full Text] [Related]
45. Effect of neonatal administration of a retroviral vector expressing alpha-L-iduronidase upon lysosomal storage in brain and other organs in mucopolysaccharidosis I mice. Chung S; Ma X; Liu Y; Lee D; Tittiger M; Ponder KP Mol Genet Metab; 2007 Feb; 90(2):181-92. PubMed ID: 16979922 [TBL] [Abstract][Full Text] [Related]
46. Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation. Keeling KM; Brooks DA; Hopwood JJ; Li P; Thompson JN; Bedwell DM Hum Mol Genet; 2001 Feb; 10(3):291-9. PubMed ID: 11159948 [TBL] [Abstract][Full Text] [Related]
47. ZFN-Mediated In Vivo Genome Editing Corrects Murine Hurler Syndrome. Ou L; DeKelver RC; Rohde M; Tom S; Radeke R; St Martin SJ; Santiago Y; Sproul S; Przybilla MJ; Koniar BL; Podetz-Pedersen KM; Laoharawee K; Cooksley RD; Meyer KE; Holmes MC; McIvor RS; Wechsler T; Whitley CB Mol Ther; 2019 Jan; 27(1):178-187. PubMed ID: 30528089 [TBL] [Abstract][Full Text] [Related]
48. Diffusion tensor imaging and myelin composition analysis reveal abnormal myelination in corpus callosum of canine mucopolysaccharidosis I. Provenzale JM; Nestrasil I; Chen S; Kan SH; Le SQ; Jens JK; Snella EM; Vondrak KN; Yee JK; Vite CH; Elashoff D; Duan L; Wang RY; Ellinwood NM; Guzman MA; Shapiro EG; Dickson PI Exp Neurol; 2015 Nov; 273():1-10. PubMed ID: 26222335 [TBL] [Abstract][Full Text] [Related]
49. Ocular Manifestations of Hurler-Scheie Syndrome: Recurrence of Host Disease in the Corneal Transplant. Kölkedi Z; Csutak A; Szalai E Mol Syndromol; 2023 Feb; 14(1):44-50. PubMed ID: 36777710 [TBL] [Abstract][Full Text] [Related]
50. Characterization of an immunodeficient mouse model of mucopolysaccharidosis type I suitable for preclinical testing of human stem cell and gene therapy. Garcia-Rivera MF; Colvin-Wanshura LE; Nelson MS; Nan Z; Khan SA; Rogers TB; Maitra I; Low WC; Gupta P Brain Res Bull; 2007 Nov; 74(6):429-38. PubMed ID: 17920451 [TBL] [Abstract][Full Text] [Related]
51. Mucopolysaccharidosis Type I and Bilateral Optic Disc Edema. Gratton SM; Neerukonda T Neuroophthalmology; 2019 Dec; 43(6):394-396. PubMed ID: 32165899 [TBL] [Abstract][Full Text] [Related]
52. Enzyme replacement therapy with laronidase (Aldurazyme Jameson E; Jones S; Remmington T Cochrane Database Syst Rev; 2019 Jun; 6(6):CD009354. PubMed ID: 31211405 [TBL] [Abstract][Full Text] [Related]
53. Temporospatial Development of Neuropathologic Findings in a Canine Model of Mucopolysaccharidosis IIIB. Harm TA; Hostetter SJ; Nenninger AS; Valentine BN; Ellinwood NM; Smith JD Vet Pathol; 2021 Jan; 58(1):205-222. PubMed ID: 33205707 [TBL] [Abstract][Full Text] [Related]
54. Hepatic storage of glycosaminoglycans in feline and canine models of mucopolysaccharidoses I, VI, and VII. Haskins ME; Otis EJ; Hayden JE; Jezyk PF; Stramm L Vet Pathol; 1992 Mar; 29(2):112-9. PubMed ID: 1632054 [TBL] [Abstract][Full Text] [Related]
55. RTB lectin-mediated delivery of lysosomal α-l-iduronidase mitigates disease manifestations systemically including the central nervous system. Ou L; Przybilla MJ; Koniar B; Whitley CB Mol Genet Metab; 2018 Feb; 123(2):105-111. PubMed ID: 29198892 [TBL] [Abstract][Full Text] [Related]
56. Changes in Corneal Clouding Over Time in Patients With Mucopolysaccharidosis. McGrath O; Sornalingam K; Aslam T; Ashworth J Cornea; 2023 Aug; 42(8):992-999. PubMed ID: 36857777 [TBL] [Abstract][Full Text] [Related]
57. The ocular features of the mucopolysaccharidoses. Ashworth JL; Biswas S; Wraith E; Lloyd IC Eye (Lond); 2006 May; 20(5):553-63. PubMed ID: 15905869 [TBL] [Abstract][Full Text] [Related]
58. Triamterene Functions as an Effective Nonsense Suppression Agent for MPS I-H (Hurler Syndrome). Siddiqui A; Dundar H; Sharma J; Kaczmarczyk A; Echols J; Dai Y; Sun CR; Du M; Liu Z; Zhao R; Wood T; Sanders S; Rasmussen L; Bostwick JR; Augelli-Szafran C; Suto M; Rowe SM; Bedwell DM; Keeling KM Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901952 [TBL] [Abstract][Full Text] [Related]
59. Evaluation of non-reducing end pathologic glycosaminoglycan detection method for monitoring therapeutic response to enzyme replacement therapy in human mucopolysaccharidosis I. Vera MU; Le SQ; Victoroff A; Passage MB; Brown JR; Crawford BE; Polgreen LE; Chen AH; Dickson PI Mol Genet Metab; 2020 Feb; 129(2):91-97. PubMed ID: 31630958 [TBL] [Abstract][Full Text] [Related]
60. Patient iPSC-derived neural stem cells exhibit phenotypes in concordance with the clinical severity of mucopolysaccharidosis I. Swaroop M; Brooks MJ; Gieser L; Swaroop A; Zheng W Hum Mol Genet; 2018 Oct; 27(20):3612-3626. PubMed ID: 30052969 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]